Abstract 8512

Article

Methods: Among 63 chemotherapy-naive and 138 pretreated FL patients receiving 4 weekly rituximab (Rituxan) doses, those responding or with stable disease were randomized to observation (n = 78) or to consolidation with 4 additional rituximab doses at 2-month intervals (n = 73).

Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in study SAKK 35/98

M.E. Ghielmini, S. Hsu Schmitz, G. Martinelli, et al

Methods: Among 63 chemotherapy-naive and 138 pretreated FL patients receiving 4 weekly rituximab (Rituxan) doses, those responding or with stable disease were randomized to observation (n = 78) or to consolidation with 4 additional rituximab doses at 2-month intervals (n = 73).

Results: In the long-term treatment group, at 5 years one-fourth of the patients were still in remission and they remain in remission at 8 years. Also, 35% of responders to rituximab induction (and 45% of chemonaive responders, P = .03) remained in remission at 8 years (P = .0001). While overall survival analysis revealed a trend favoring prolonged treatment (P = .09), a meta-analysis including 4 trials showed a significant increase in overall survival with maintenance rituximab vs no maintenance. Univariate analysis showed stage (P = .02), bulk (P = .01), prior chemotherapy (P = .001) and FcR phenotype to be prognostic factors for event-free survival (EFS). The only significant prognostic factor for EFS in a multivariate Cox regression, however, was having received consolidation rituximab (hazard ratio = 0.6, P = 0.007). Previous treatment, stage, and 158-phenotype of the Fc receptor were not predictive of response.
Among grade 3/4 toxicities, neutropenia was reported in 16% of patients in the standard arm and 17% in the prolonged treatment arm. There were 22 cases of second malignancy (12 standard arm/10 prolonged treatment arm).

Conclusions: It appears that the EFS advantage of prolonged vs short-course rituximab continues for many years after the end of treatment. Patients treated with 8 doses of rituximab over 1 year had approximately a 25% likelihood of remaining in remission at both 5 years and at 8 years.

Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
A panel of 4 experts on multiple myeloma
A panel of 4 experts on multiple myeloma
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Balazs Halmos, MD, with the Oncology Brothers presenting slides
Although no responses were observed in 11 patients receiving abemaciclib monotherapy, combination therapies with abemaciclib may offer clinical benefit.
Related Content